share_log

Litchfield Hills Initiates Coverage On Mateon Therapeutics with Buy Rating, Announces Price Target of $3

Benzinga Real-time News ·  Dec 7, 2020 20:25

Litchfield Hills initiates coverage on Mateon Therapeutics (OTC:MATN) with a Buy rating and announces Price Target of $3.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment